Article Details

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 Vs Placebo

Retrieved on: 2025-06-29 12:52:38

Tags for this article:

Click the tags to see associated articles and topics

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 Vs Placebo. View article details on hiswai:

Excerpt

Invivyd recently announced its phase 3 CANOPY trial evaluating monoclonal antibody, pemivibart (Pemgarda) against COVID-19 had been published in ...

Article found on: www.contagionlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo